
    
      The purpose of this study is to determine the progression-free survival (PFS) rate assessed
      12 weeks after the initiation of IMC-A12 monotherapy, administered every 2 weeks to
      participants with previously-treated, advanced or metastatic soft tissue and Ewing's
      sarcoma/PNET.
    
  